

TRIALSWEST EXPANDS WITH NEW CLINICAL TRIAL SITE

Highlights

- TrialsWest continues its expansion with a third clinical trial site to open in Mandurah, WA
 - New site expected to open in August and provide significant additional service capacity
 - Near term growth expected from participant recruitment for the current major pharma trial being managed by the Resonance Health Group
 - Third site also allows additional participant recruitment into other existing trials being serviced by TrialsWest out of its existing two sites
-

Resonance Health Limited (**Resonance** or **Company**) (ASX: RHT) is pleased to announce further expansion of the TrialsWest business with the expected August 2025 opening of a third TrialsWest trial site in Mandurah, Western Australia (**Mandurah Site**).

The new Mandurah Site is ~72km south of Perth, and ~60km from the nearest TrialsWest site located in the Perth suburb of Spearwood (**Spearwood Site**). The addition of the Mandurah Site significantly increases the business's participant capacity and enables the Resonance Health group to further capitalise on its existing clinical trial workflows, most notably the major pharma clinical trials being managed by the group.

The City of Mandurah is one of the fastest growing cities in Australia. In 2024 it was identified as the fastest growing city in the country with a 91% growth in population over the past 20 years, equating to an additional 30,000 residents¹. It is the second most populous city in Western Australia with a population of approximately 105,000 people (excluding surrounding suburbs). It is also the state's largest regional city covering an area of 174 square kilometres².

The Mandurah Site is the next step in Resonance Health's expansion strategy for TrialsWest and is consistent with the aspirations communicated at the time of TrialsWest's acquisition by Resonance Health (see ASX releases, 31 May 2023 and 2 April 2023). This strategy is focused on delivering growth from a diverse spread of pharma customers and trials over multiple years.

The addition of this new site is also consistent with targeting new clinical trial sites in affordable densely populated areas with good transport, car parking and accessibility links, and with low establishment costs – for example, where the sites are already fitted out or can be fitted out at a modest cost to Resonance Health. Further new sites will be targeted in coming periods along with complementary acquisitions.

Resonance Health CEO, Mr. Andrew Harrison commented:

"We are very pleased with the next phase of growth of the TrialsWest business, and we continue to believe in the significant opportunity it represents as a platform for future growth."


¹ Australian Broker, 9 May 2024, Mina Martin: <https://www.brokernews.com.au/news/breaking-news/what-is-australias-fastestgrowing-city-284664.aspx>

² City of Mandurah facts and figures: <https://www.mandurah.wa.gov.au/learn/about-mandurah/fact-and-figures>

To watch Mr Harrison's video discussion about the expansion, please visit the Company's InvestorHub:

<https://investors.resonancehealth.com/link/peg70e>

TrialsWest Network:



Further Information: <https://investors.resonancehealth.com>

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact:

Andrew Harrison – Chief Executive Officer

E: andrewh@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis

The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US



/Resonance-Health-Ltd



/ResonanceHealth



/ResonanceHealthLtd